Tonacea Announces 15th Anniversary Global Biotech Frontier Conference Agenda and Files IPO Prospectus
Amid the surging tide of “fast-follow,” where is China’s pharmaceutical industry—standing at a major inflection point in its transition from generics to comprehensive innovation—headed?
There is no choice but to discover new drugs that truly meet clinical needs and deliver market value, and to accelerate their launch in China and globally.
Addressing this monumental challenge requires a completely new set of solutions. The key to success lies in reengineering and optimizing the new drug R&D process by leveraging deep insights into clinical needs, mastering cutting-edge global biopharmaceutical technologies, and staying abreast of constantly evolving pharmaceutical regulatory trends.
Pioneering New Drugs in China, Empowering Innovative Development. The inaugural "Global Conference on Frontier Biopharmaceutical Technologies and Policy & Regulations" (comprising one main forum and seven sub-forums) will be held from October 30 to November 1 by Jinji Lake in Suzhou. Numerous presentations and roundtable discussions will directly address key pain points in China’s pharmaceutical industry:
Who Can Become the “Huawei of Pharma”?
Has the Time Come for Developing Original New Drugs?
How to Stand Out in Homogenized R&D?
What Will Be the Next Blockbuster After PD-1?
How to Respond to the Crisis Caused by the Scarcity of Drug Targets?
Innovation in Antibody Drugs: What Can We Do in the Future?
How Can Cell Therapy Break Through in the Treatment of Solid Tumors?
How Can R&D Institutions Navigate the MAH Path?
……
In October, Tongxieyi will celebrate its 15th anniversary and cordially invites you to attend this conference, joining top global scientists, regulatory experts, and clinical specialists in the biopharmaceutical industry to shape the next decade of innovative drug development in China.
Policy Orientation for Innovative New Drugs in China
Invited Keynote Speaker
Opportunities and Challenges in the Development of China's Biopharmaceutical Industry
Professor Gao Fu: Academician of the Chinese Academy of Sciences, Director of the Chinese Center for Disease Control and Prevention
U.S. Biotechnology Development: Innovation and Breakthroughs
Dr. William J. Rutter: Member of the U.S. National Academy of Sciences, Co-discoverer of HCV, Chairman of Synergistic LLC
Antitumor Drug Development Based on Innate Immunity
Invited Keynote Speaker
Policy Orientation to Accelerate Drug Review and Approval
Dr. Xu Zengjun: Chief Scientist, Center for Drug Evaluation, National Medical Products Administration
Who Can Become China’s “Huawei of Pharmaceuticals”?
Professor Li Jin: Director of the Department of Oncology, Shanghai East Hospital; Chairman of the Chinese Society of Clinical Oncology (CSCO)
Thirty Years of Turbulence (2005–2035): A Review and Outlook, with an Analysis of the Future Development Path for Chinese Pharmaceutical Enterprises
Professor Zhu Xun: Chairman of the Tongxieyi New Drug Talent Club
Frontier Technologies and Development Trends in Biologics
Dr. Yu Dechao: Chairman of Innovent Biologics
Clinical Medication Needs and Drug Innovation in Neurological Diseases
Professor Wang Yongjun: Executive Vice President of Beijing Tiantan Hospital
Unmet Clinical Needs in Pharmacotherapy and Drug Development for Liver Diseases
Professor Niu Junqi: Deputy Dean, Institute of Translational Medicine, The First Hospital of Jilin University
Translational Medicine and Recent Advances in Lung Cancer
Professor Zhou Caicun: Chairman of the CSCO Non-Small Cell Lung Cancer Committee, Director of the Institute of Oncology, School of Medicine, Tongji University
Antibody and CAR-T Drug Innovation: What Can We Do?
Dr. Liu Cheng: Founder and CEO of UREKO Biotech, USA
Independent Innovation: Achieving Breakthroughs in Original Biologics
Dr. Fang Jianmin: CEO and Chief Scientist of RemeGen
SHP2 and KRAS Pathways: The Next Wave of Blockbusters After PD-1
Dr. Wang Yinxiang: Chairman of Jacobio Pharmaceuticals
Good Science Enables New Drug Development to Triumph Over Strength with Weakness
Dr. Xie Yuli: General Manager and Executive Director of Suzhou Ouling Bio
The Desire-Driven Industry and the U.S. Pharmaceutical Legal Landscape
Meng Bayi: Special FDA Commentator for Tongxieyi
Roundtable Forum: How Can China’s New Drugs Break Through in the Next Decade?(Proposed Guests)
Du Ying: Chairperson of Zai Lab
Zhang Lianshan: Vice President of Hengrui Medicine
Wu Xiaobin: General Manager of BeiGene China and President of the Company
He Ruyi: Chief Scientist, SDIC Innovation Medical Health
Lu Xianping: CEO of Chipscreen Biosciences
Li Ning: Executive Director and General Manager of Junshi Biosciences
Jiang Ningjun: CEO of CStone Pharmaceuticals
Yang Dajun: Chairman of Ascentage Pharma
Chen Li: Chairman of Hua Medicine
Tongxieyi 15th Anniversary Gala and China Pharmaceutical Innovation Figures Awards Ceremony(Invitation by Direction)
Forum One AntibodyDrug Discovery and Innovation:What Can We Do in the Future
International Frontiers in Antibody Development: New Targets and Novel Technology Platforms
[Chairman] Lu Hongtao(Co-founder and CSO of Kewang Pharmaceutical)
[Planner] Chen Mingjiu(Founder and CEO of Bio-Aus)
Wang Jun(Researcher at New York University, USA)
Lv Zhijian(Former Head of Biologics Research and Innovation at Novartis China)
Forum 2 New TypeAntibody Industrialization Development:Bispecific Antibodies and Beyond
Antibody Engineering, Quality Control, Clinical Trials, Industrialization Technologies, and Policies and Regulations
[Chairman] Zhu Zhenping(President of R&D and CSO, 3SBio)
[Planner] Shen Wenyan(Senior Vice President, NGM Biopharmaceuticals)
Gu Jijie(Chief Scientific Officer and Executive Vice President, WuXi Biologics)
Forum III CellImmunotherapy:A New Era of Pharmacological Intervention
Innovation in the R&D of CAR-T Cell and Gene Therapy Drugs
[Chairman] Liu Cheng(Founder of UroGen Biotech, USA)
[Planning] Xu Zhongwei(Chairman of Beisert Biotech)
Zhang Yu(CEO of Yi'ang Biotech)
Du Xin(Senior Vice President of Arno Therapeutics, Hangzhou)
Forum Four From the sameStand Out in Qualitative R&D:Innovative Drug Project Initiation and Clinical Development
Project Initiation Assessment, Target Evaluation, Translational Medicine, Clinical R&D, AI and Drug Discovery
[Chairman] Lu Xianping(CEO of Chipscreen Biosciences)
[Planning] Li Jing(Founder of Yaodu)
Xie Yuli(General Manager of Ouling Biology)
Wang Zaiqi(Founder of YingShi Biopharma)
Peng Bin(BioMap CMO)
Zou Jianjun(Vice President of Hengrui Medicine)
Du Tao(Chief Advisor, HPC)
Li Xing(Founder of DeepGlow)
Forum Five Chemical DrugsKey Breakthroughs in Pharmaceutical Development and Practical Implementation of the MAH System for R&D Institutions
Pharmaceutical Development of Drug Substances and Drug Products, Clinical Sample Manufacturing, and MAH Practical Operations
[Chairman] Wu Zhenping(Senior Vice President, Hutchison MediPharma)
Guo Ming(Co-founder of Ascentage Pharma)
Forum VI The Path to Innovation in Modified Drugs
[Chairman] Zhao Xiaobin(Founder of The WhiteOak Group)
Tong Weiqin(President of Aosta Pharmaceuticals, USA)
[Planner] Wen Hong(Livzon Group CSO)
Wang Qingsong(CEO of Nanjing Qingpu Biotech)
Forum 7 BiologyOpportunities and Risks in Pharmaceutical Investment
[Chairman] Wu Qinggong(Vice President of the China Pharmaceutical Enterprise Management Association and Director of the Investment and Financing Working Committee, H50 Council Member)
Hong Tan(Managing Director, Legend Capital)
[Planner] Tan Yong(Editor-in-Chief of E-Pharma Manager, Secretary-General of H50)
Honorary Support
Media Support
Registration Method
Tongxieyi Members:Exclusive Benefits!All-inclusive tickets fromCNY 1,200/person
For membership applications, please contact the Tongxieyi Secretariat via WeChat: txymsc
General Attendees:Pass tickets offer discounts of up toCNY 2,500/person
Register Early for Lower Prices, Register Late for Higher Prices
Sub-forum Admission Ticket:2000 yuan/person
(Excluding admission tickets to the main forum)
On-site Registration:RMB 4,000/person
(Registration after October 29)
